THE EFFECT OF ARTIFICIAL LIVER PLASMADIAFILTRATION COMBINED WITH ENTECAVIR ON SHORT-TERM CURATIVE EFFECT, LIVER FUNCTION, AND HBV-DNA NEGATIVE CONVERSION RATE IN THE TREATMENT OF CHRONIC SUBACUTE LIVER FAILURE

Yijun Zeng¹, Yingmin Luo¹, Sheng Guo¹, Longyuan Bao1, Xinhua Li^{2, *}

¹Department of Hepatology, Ganzhou Fifth People's Hospital, Ganzhou, Jiangxi, 341000, China - ²Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510600, China

Objective: To explore the effects of artificial liver plasma diafiltration (PDF) combined with entecavir in the treatment of patients with chronic and subacute liver failure on short-term efficacy, liver function, and hepatitis B virus deoxyribonucleic acid (HBV-DNA) conversion rates.

Methods: A total of 86 patients with chronic and subacute liver failure who were treated in our hospital from January 2019 to March 2020 were randomly selected and divided into a study group and control group with 43 patients each. Patients in the control group were treated with artificial liver PDF, and patients in the study group were treated with artificial liver PDF combined with entecavir. The clinical efficacy of treatment in the 2 groups was compared. The end-stage liver disease model score (MELD) and alanine aminotransferase (ALT), total bilirubin (TBIL), and aspartate transferase (AST) levels were measured before and after treatment in the 2 groups. Additionally, changes in the HBV-DNA negative conversion rate were measured at 4 weeks, 8 weeks, and 12 weeks after treatment in both groups, and the occurrence of adverse reactions was recorded.

Results: The total treatment efficacy rates in the study group and the control group were 95.35% and 79.07%, respectively, with the rate being significantly higher in the study group than in the control group (P<.05). Compared with before treatment, the MELD score and TBIL, ALT, and AST levels were significantly reduced after treatment in both groups, and the values in the study group were significantly lower than in the control group (P<.05). At 4 weeks, 8 weeks, and 12 weeks after treatment, the HBV-DNA negative conversion rate of the study group was significantly higher than that of the control group (P<.05 or P<.01). The incidence of adverse reactions in the study group and the control group was 6.98% and 25.58%, respectively, with the incidence in the study group being significantly lower than in the control group (P<.05).

Conclusion: Artificial liver PDF combined with entecavir for the treatment of chronic subacute liver failure can significantly improve clinical efficacy, promote HBV-DNA negative conversion, improve liver function, and reduce the occurrence of adverse reactions. Thus, this approach is worthy of clinical application and promotion.